联合免疫模式在晚期非小细胞肺癌治疗中的研究进展

Research progress of combined immunotherapy mode in the treatment of advanced non-small cell lung cancer

近年来,随着分子免疫学及相关生物技术的快速发展,免疫治疗在肿瘤治疗方面取得了突破性进展。对免疫检查点抑制剂,特别是程序性死亡受体-1及其配体(PD-1/PD-L1)抑制剂的研究,使肿瘤治疗进入了一个新阶段。临床上,免疫检查点抑制剂与传统治疗手段相结合的联合治疗模式发挥着越来越重要的作用。在众多联合免疫治疗模式的研究中,对晚期非小细胞肺癌的治疗研究尤为深入。鉴于此,我们回顾了近年来多项重要的联合免疫治疗晚期非小细胞肺癌的临床研究,包括免疫联合化疗、免疫联合放疗及免疫联合抗血管生成药物,对其作用机制、临床疗效及不良反应进行了总结分析,以期对临床应用提供参考。

In recent years,with the rapid development of molecular immunology and related biotechnology,immunotherapy has made breakthrough progress in the treatment of cancer.The research on immune checkpoint inhibitors,especially programmed death-1 and its ligand(PD-1/PD-L1)inhibitors,has brought cancer therapy into a new stage.In clinical practice,the combined therapy mode of immunotherapy with traditional treatment methods,is also playing an important role in cancer treatment.Among the studies on combined immunotherapy modalities,the treatment of advanced non-small cell lung cancer has been particularly in-depth.We reviewed recent important clinical studies of combined immunotherapy for advanced non-small cell lung cancer,including the commbination with chemotherapy,radiotherapy and anti-angiogenic drugs,and further summarized their mechanism,clinical efficacy and adverse reactions,with a view to providing a reference for clinical application.